Thalidomide levels in patients with erythema nodosum leprosum.

Abstract

Thalidomide is used for the acute treatment and suppression of the cutaneous manifestations of erythema nodosum leprosum (ENL). In this study, comparisons were made regarding the plasma concentrations of thalidomide in patients with ENL on the course or after leprosy therapy in a prospective clinical trial. Thalidomide concentrations were measured by liquid chromatography on days 1, 3, and 14 of treatment. After 100 mg/d, the thalidomide concentrations ranged from 0.82 to 1.03 and 0.43 to 0.80 microg/mL, on the course or after leprosy therapy, respectively. No differences were observed in thalidomide concentrations between and within the groups. Our results suggested that leprosy multidrug therapy does not seem to affect the plasma concentrations of thalidomide in patients with ENL.

• Authors: José Luiz Fernandes Vieira, Maria do Socorro da Silva Valente
• Journal: Therapeutic drug monitoring (Ther Drug Monit) Vol. 31 Issue 5 Pg. 602-3 (Oct 2009) ISSN: 1536-3694 [Electronic] United States
• PMID: 19704404 (Publication Type: Journal Article)

Chemical References

• Leprostatic Agents
• Thalidomide

Topics

• Adult
• Chromatography, Liquid (methods)
• Erythema Nodosum (blood, drug therapy)
• Humans
• Leprostatic Agents (blood, therapeutic use)
• Leprosy, Lepromatous (blood, drug therapy)
• Male
• Metabolic Clearance Rate
• Thalidomide (blood, metabolism)
• Vasculitis (chemically induced, drug therapy)
• Young Adult